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Telemedicine and Telehepatology 
During the COviD-19 Pandemic
Oren K. Fix, M.D., M.Sc., F.A.A.S.L.D., * and Marina Serper, M.D., M.S. †,‡
Telemedicine has always had the potential to improve 
access and reduce the costs of health care. Because of the 
coronavirus disease 2019 (COVID-19) pandemic, telemedi-
cine has now become a critical way to deliver clinical care.1 
Early in the pandemic, the Centers for Disease Control and 
Prevention (CDC) recommended that ambulatory facilities 
delay elective visits to mitigate SARS-CoV-2 transmission 
among patients and health care workers.2 Hospitals and 
health systems across the United States appropriately can-
celed nonurgent clinic visits and procedures, which led to a 
sudden and urgent need to shift to alternative health care 
delivery models for triage, assessment, and patient care.2 
Telemedicine, which includes office visits and other med-
ical services provided at a distance using interactive two-
way telecommunications systems (i.e., real-time audio and 
video),3 has the potential to limit the exposure of patients 
and health care workers to the clinic environment, help 
preserve the limited supply of personal protective equip-
ment (PPE), and reduce the backlog of deferred patient 
care resulting from the COVID-19 pandemic response. In 
turn, this may mitigate the risks for decompensation, mor-
bidity, and loss to follow-up that could result from delayed 
care for patients with liver disease.4 A few prescient hos-
pital systems had already implemented telemedicine pro-
grams prior to the pandemic, but the vast majority had 
not, due in large part to federal and state regulatory and 
reimbursement limitations.
There are many reasons why telemedicine had not 
gained a foothold in the United States prior to the COVID-
19 pandemic. The Centers for Medicare and Medicaid 
Services (CMS) places substantial barriers to the use of 
telemedicine by restricting it to patients who reside in rural 
areas and who must travel to a local medical facility (e.g., 
doctor’s office, hospital, dialysis facility, or skilled nursing 
facility) to receive telemedicine services from a doctor in a 
remote location.3 Most private payers cover some telemed-
icine services, and many states have enacted parity laws 
that require private payers to reimburse the same amount 
for telemedicine services as analogous in-person services. 
In many cases, however, reimbursement for telemedicine 
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services is lower than in-person services. In addition to the 
regulatory and reimbursement issues, implementation of 
telemedicine is limited by technology requirements, such 
as Health Insurance Portability and Accountability Act 
(HIPAA)-compliant audiovisual equipment. As a result, 
telemedicine adoption has been slow.
US lawmakers recognized the critical need to remove 
barriers to telemedicine care during the COVID-19 crisis. 
The Coronavirus Preparedness and Response Supplemental 
Appropriations Act (H.R. 6074) was signed into law on 
March 6, 2020, and provides a temporary waiver of many 
of the CMS restrictions and requirements regarding tele-
medicine services during the COVID-19 public health emer-
gency.5 Specifically, the bill waives the rural area requirement 
and the originating site restrictions, allowing the patient to 
be located anywhere, including their home, and telemed-
icine services will be paid at the same amount as in-per-
son services. On March 17, 2020, the Health and Human 
Services Office of Civil Rights announced that it would not 
impose penalties for the good faith provision of telemedi-
cine during the COVID-19 public health emergency, even 
if the technologies used may not fully comply with HIPAA 
requirements.6 Recently, on April 30, 2020, the CMS an-
nounced it would temporarily increase payments for tele-
phone visits to match in-person and video visits.7 Barriers 
to interstate licensure have largely been lifted. Most states 
have temporarily waived interstate licensure requirements, 
whereas others have enabled rapid provision of medical li-
censure during the current public health emergency.
When these barriers to telemedicine were removed, 
providers, hospitals, and health systems rapidly embraced 
telemedicine or scaled up existing programs to meet the 
sudden demand for remote, synchronous patient care. As 
a result, there has been a sudden and substantial increase 
in telemedicine visits for urgent and nonurgent ambula-
tory care both related and unrelated to COVID-19, and 
patient satisfaction for telemedicine care has been consis-
tently high.8
The CDC identifies patients with liver disease and im-
munosuppressed patients to be at higher risk for severe 
COVID-19.9 It is therefore imperative that we minimize ex-
posure of patients with liver disease and liver transplant re-
cipients to the health care environment. “Telehepatology,” 
or telemedicine for advanced liver disease, has the poten-
tial to facilitate care of this vulnerable population during 
this critical time.10
Despite its promise, telehepatology is not a panacea. 
Some patients with new physical symptoms or recent he-
patic decompensation are best evaluated in person but may 
avoid seeking medical care due to social distancing poli-
cies or concerns about exposure to COVID-19 in the health 
care setting. Patients in need of liver transplantation may 
be challenging to evaluate because of the need for phys-
ical examination, frailty assessment, building rapport, and 
observing interactions among family members and other 
caregivers. It is difficult to initiate a potentially lifelong pro-
vider-patient relationship via video. In the nontransplant 
setting, telemedicine may be challenging for new patients 
without an established patient-provider bond or who re-
quire discussions about serious illness or end-of-life conver-
sations. More prospective data are needed in these settings.
In contrast, telehepatology for liver transplant evalua-
tions may present an opportunity to more efficiently triage 
patients and expedite the time from referral to evaluation 
and listing.11 It can more readily identify patients with psy-
chosocial or other barriers to transplantation and prevent 
futile evaluations12 (Table 1). The innovative use of tele-
hepatology could allow some transplant evaluations to 
occur on-site while limiting the proximity of physicians and 
other team members to patients, a concept coined by our 
emergency medicine colleagues as “electronic PPE.”13 For 
established patients without fibrosis, with stable chronic 
liver disease (e.g., viral hepatitis, metabolic-associated 
fatty liver disease), or with benign liver lesions, for exam-
ple, telemedicine can add convenience and efficiency. For 
established patients with decompensated liver disease, 
TaBle 1. PrOs anD COns OF TeleHePaTOlOGY FOr liver TransPlanT evalUaTiOn
Pros Cons
• Limit exposure of patients and health care workers to SARS-CoV-2
• Preserve PPE
• Efficiently triage patients in need of urgent in-person evaluation
• Expedite time from referral to evaluation and listing
• Identify barriers to transplantation and avoid futile evaluations
• Difficult to build rapport and initiate a potentially lifelong provider-patient 
relationship
• Limited physical examination (e.g., signs of decompensation, assessment of frailty)
• Difficult to observe interactions among family members and other caregivers
• Not suitable for all patients (e.g., very ill, difficulty with the technology or technology 
not available)
• Uncertain feasibility/sustainability following COVID-19 public health emergency
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telemedicine can offer rapid evaluation and avoid the need 
for an in-person appointment when, for example, adjust-
ing diuretics or medications for hepatic encephalopathy. 
Caregivers may also be more readily available to join tele-
medicine visits rather than take time away from work and 
other duties. An example of telehepatology workflow is 
illustrated in Fig. 1.
As incident cases of COVID-19 decrease, we will need 
to adopt a gradual, stepwise approach to the “reentry” 
process as we start to move clinical activities toward a 
prepandemic state. We must continue to limit in-person 
patient care where it is appropriate to avoid a “second 
wave” of SARS-CoV-2 transmission. Even when in-person 
clinic visits and procedures are an option for most patients, 
many will still prefer telemedicine alternatives to in-person 
care partly out of fear of coming to the clinic or hospital.4 
Patients will largely dictate when they are ready to return 
to “business as usual,” and telemedicine will continue to 
be an important part of getting us there.
As we look to a future beyond the COVID-19 pan-
demic, we have an opportunity to consider telemedicine’s 
place in the routine delivery of patient care. Telemedicine 
has the potential to improve patient care and satisfaction, 
and improve the way we evaluate patients for transplan-
tation; it need not only serve its current purpose as a tem-
porary solution during a crisis. There are many problems 
other than COVID-19 that may be solved by telemedicine, 
including disparities in quality and access to health care 
in both urban and rural areas and the escalating cost of 
health care.14 Rather than force most patients and pro-
viders into a remote care delivery model, as we have had 
to do during the pandemic, we can strategically use tele-
medicine for both triage and routine care where it is most 
appropriate.
Our patients have much to gain from the widespread 
adoption of telemedicine during the COVID-19 pandemic 
and beyond. Patients are already embracing this mode of 
care delivery. For our part as health care professionals, we 
will need to learn how to more efficiently integrate tele-
medicine as one option in our routine care.14 We will need 
to learn new skills for conducting telemedicine visits and 
develop programs to educate and mentor colleagues and 
trainees.8 We need to implement and study care pathways 
for different patient populations and determine what is 
the right patient phenotype and “dose” of telemedicine 
to optimize convenience, efficiency, and patient-centered-
ness without compromising clinical care. These answers 
will undoubtedly vary because of payment strategies, pa-
tient preferences, geography, local resources, and provider 
acceptance, among other factors. For telemedicine to re-
main viable in the future, we need to advocate for legisla-
tive reform at the federal and state levels to preserve many 
of the current waivers that permit telemedicine services. 
These changes will need to be thoughtfully considered and 
implemented in a way that is financially sustainable and 
maximizes patient safety and privacy. There is reason to 
hope that this is possible. While the world is ravaged by 
COVID-19, perhaps one desirable lasting effect may be the 
fulfillment of the promise of telemedicine.
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